Amrn stock forecast options open interest in AMRN has risen

Options open interest in AMRN has risen steadily, reflecting increasing speculative positioning. A bullish amrn stock forecast scenario aligns with call volume outweighing puts by a 2:1 ratio. Given that Amarin actually had positive free cash flow last year, before burning cash this year, we'll focus on its operating revenue to get a measure of the business trajectory. Regrettably, the company's operating revenue moved in the wrong direction over the last twelve months, declining by 25%. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . Invitae Corp shares have fallen about 73% over the past one year. But earlier this month Invitae Corporation (NYSE:NVTA) jumped after the FDA gave a go-ahead to Invitae Common Hereditary Cancers Panel, a test to identify cancer-related genes. Year-to-date performance in AMRN is lagging the biotech index, but analysts note potential catalysts in EU approvals. The amrn stock forecast could shift sharply upward upon credible partnership announcements.